Trial Profile
Open Label, Study to Determine the Pharmacokinetic Interactions of Steady State Tipranavir/Ritonavir (500/200 mg) and Steady State Ribavirin and Pegylated Interferon Alfa 2a in HIV Negative, HCV Infected Subjects With Mild Hepatic Impairment and the Pharmacokinetic Properties of Tipranavir/Ritonavir in HIV Negative, HCV, HBV, Hepatitis Delta Infected Subjects or Alcoholic Cirrhosis Subjects With Moderate Hepatic Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tipranavir (Primary) ; Peginterferon alfa-2a; Ribavirin; Ritonavir
- Indications Alcoholic cirrhosis; Hepatitis B; Hepatitis C; Hepatitis D; Liver disorders
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 14 Oct 2014 New trial record